Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses

Addex Therapeutics

28/09/2026 06:10

Overview
Switzerland biopharma firm's Q2 net loss narrowed yr/yr as R&D expenses declined
Company raised USD 2.8 mln via ATM offering to fund clinical development
Cash and cash equivalents fell to CHF 0.8 mln at June 30, 2026 from CHF 2.3 mln yr earlier

Outlook
Neurosterix expected to complete Phase 1 study of NTX-253 in Q4 2026
Company to advance GABAB chronic cough program toward clinical development
Addex expects to progress GABAB PAM program for substance use disorders after regaining rights

Result Drivers
LOWER R&D COSTS - Co said reduced outsourced R&D expenses and fewer services from Neurosterix drove decline in R&D costs
ATM FUNDING - Co raised USD 2.8 mln (CHF 2.2 mln) via ATM offering to support clinical development
PROGRAM RIGHTS REGAINED - Co regained rights to GABAB positive allosteric modulator portfolio for substance use disorders from Indivior

Company press release: ID:nGNE3Gvcj6

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
CHF 0.01
 
Q2 Net Loss
 
CHF 1.75 mln
 
Q2 Operating Income
 
-CHF 645,000
 

Reuters Recommended Reads
Sept 25 - US FDA approves Mirum's drug for rare bone disorder
Sept 25 - ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)